Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves rucaparib for ovarian cancer

The US Food and Drug Administration (FDA) has approved rucaparib (Rubraca; Clovis Oncology) for ovarian cancer in women with BRCA mutations.

The drug, a poly-adenosine diphosphate-ribose polymerase (PARP) inhibitor, is indicated for women with advanced disease who have been treated with two or more chemotherapies. A BRCA mutation must be identified via a designated FDA-approved diagnostic test.

The drug was approved via the FDA’s accelerated programme and the decision was based on a surrogate endpoint of overall response rate. Data were taken from two single-arm trials involving 106 patients, 96% of whom had a confirmed BRCA mutation.

The trials reported an overall response rate of 54% — the percentage of patients who had a complete or partial shrinkage of their tumours. The most common side effects included nausea, vomiting, anaemia, abdominal pain and diarrhoea. The most serious adverse events were myelodysplastic syndrome, acute myeloid leukaemia and fetal harm. Confirmatory studies are ongoing with progression-free survival as an end point.

The FDA recommends that patients are monitored for haematologic toxicity throughout treatment.

Sir Harpal Kumar, chief executive of Cancer Research UK, says the charity is delighted by the approval, noting that UK-based researchers funded by the charity were involved in discovering and developing the drug in the early 1980s.

“The drug — one of an exciting group of drugs that exploit the weaknesses cancer cells have in repairing damaged DNA — will offer new hope to women with advanced ovarian cancer. We hope it could one day treat other cancer types and clinical trials are under way to discover its potential.”

Clovis Oncology submitted a marketing authorisation application to the European Medicines Agency in November 2016.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20202127

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • US Food and Drug Administration building

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.